CRB Expert Publishes Peer-Reviewed Paper on Safe, Compliant ADC Manufacturing
Nov 16, 2026
Nov 16, 2026

Ashley Harp examines containment, process safety and regulatory considerations as demand grows for antibody-drug conjugates (ADCs) and other complex therapeutics
CRB, a global provider of engineering, architecture, construction and consulting solutions, announced today Ashley Harp, Fellow, Containment & Bioconjugates, has published a peer-reviewed article in AAPS PharmSciTech, an official journal of the American Association of Pharmaceutical Scientists (AAPS). It examines what manufacturers need to consider as antibody-drug conjugates (ADCs) move toward commercial production.
The article, “Antibody-Drug Conjugate Manufacturing: Facility Design, Process Safety, and Regulatory Considerations” examines manufacturing, formulation and fill/finish challenges associated with ADCs. It pays particular attention to cytotoxic products and the risks they present to personnel, facilities and the environment.
The article also covers regulatory expectations, including EU GMP Annex 1, and strategies to prevent cross-contamination and personnel exposure.
“ADC manufacturing presents a unique set of challenges because it requires the integration of highly potent compounds with complex biologic processes, each bringing its own safety, containment and regulatory considerations,” stated Harp. “As interest in these therapies continues to grow, manufacturers need to think holistically about process design, facility requirements and risk mitigation from the outset. My goal with this paper was to help clarify these considerations and provide a framework for approaching ADC manufacturing safely and compliantly.”
The publication comes as demand for that expertise is growing. CRB’s Horizons: Life Sciences 2026 report, based on insights from more than 400 global life science leaders, found that every modality tracked in the survey, including ADCs, saw increased manufacturing interest compared with 2025. The report also highlights the industry’s focus on improving manufacturing efficiency, managing workforce constraints and investing in facilities and technologies that can support long-term growth. As ADC pipelines advance, manufacturers will need to align facility investments with both current production requirements and future portfolio needs.
Key considerations covered in the article include:
Read the full review, “Antibody-Drug Conjugate Manufacturing: Facility Design, Process Safety, and Regulatory Considerations”, in AAPS PharmSciTech: https://link.springer.com/article/10.1208/s12249-026-03502-7.